Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.67 |
| ▸ | FABP4 | P15090 | 1/20 | 0.67 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.52 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2936357 | 0.98 | FABP3 (0.65) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL17468452 | 0.86 | FABP3 (0.62) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL2939291 | 0.85 | SCN2A (0.54) | FABP3FABP4CYP3A4CYP2C19SCN2A | |
| SCHEMBL13853666 | 0.84 | LIPG (0.60) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL25334554 | 0.81 | FABP3 (1.00) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL13212055 | 0.80 | POLB (0.62) | FABP3FABP4LIPGSCN2ASCN10A | |
| SCHEMBL2558725 | 0.80 | FABP3 (0.59) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL10672043 | 0.79 | FABP3 (0.61) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL2558196 | 0.78 | KMT2A (0.59) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL5795219 | 0.78 | KDM4E (0.52) | FABP3FABP4LIPGCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-1704148-B1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON INC (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005063763-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | FABP3 323/4885FABP4 1901/4885LIPG 510/4885 |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | FABP3 1187/4885FABP4 1138/4885LIPG 632/4885 |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | FABP3 1187/4885FABP4 1138/4885LIPG 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.